Thus, while longer term treatment with GLP-1 receptor agonists clearly reduces fasting triacylglycerol and LDL-cholesterol levels (perhaps, in part, related to body weight reduction) and suppresses the formation of chylomicrons and postprandial increases in triacylglycerol, lipoprotein concentrations do not seem to be affected by antagonising physiological concentrations of endogenously secreted GIP in type 2 diabetes. This evidence concerns the gene GIP and type 2 diabetes mellitus.